Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections six months after vaccination. This highlights the importance of routine testing of COVID-19 IgG Spike, semi-quantitative antibodies post-vaccination, particularly among immunocompromised patients.
CITATION STYLE
Pasikhova, Y., Morrison, A. R., Katzman, J. H., & Syed, M. (2022). Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection. Cancer Control, 29. https://doi.org/10.1177/10732748211070720
Mendeley helps you to discover research relevant for your work.